C07K 14/4736
Retinoblastoma protein
Official title: {Retinoblastoma protein}
C07K14/4736 (Retinoblastoma protein) appears on 43 US grants and 32 published applications in this corpus.
Search patents in C07K- Granted patents
- 43
- Published applications
- 32
- Assignees
- 23
- Inventors
- 80
- Latest grant
- 10 Dec 2024
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1994 | 1 | 0 |
| 1995 | 2 | 0 |
| 1996 | 3 | 0 |
| 1997 | 1 | 0 |
| 1998 | 7 | 0 |
| 1999 | 3 | 0 |
| 2000 | 5 | 0 |
| 2001 | 4 | 0 |
| 2002 | 1 | 3 |
| 2003 | 5 | 6 |
| 2004 | 0 | 3 |
| 2005 | 1 | 2 |
| 2006 | 2 | 3 |
| 2007 | 1 | 1 |
| 2008 | 2 | 2 |
| 2009 | 0 | 3 |
| 2010 | 0 | 0 |
| 2011 | 0 | 1 |
| 2012 | 0 | 0 |
| 2013 | 0 | 0 |
| 2014 | 0 | 1 |
| 2015 | 0 | 0 |
| 2016 | 0 | 1 |
| 2017 | 0 | 0 |
| 2018 | 1 | 1 |
| 2019 | 0 | 1 |
| 2020 | 1 | 0 |
| 2021 | 1 | 3 |
| 2022 | 0 | 0 |
| 2023 | 1 | 0 |
| 2024 | 1 | 0 |
| 2025 | 0 | 1 |
By publication year. Applications have been published since 2001.
Recent patents
- Cyclic peptide for treating cancer10 Dec 2024US 12,162,959 B2Saint Leo University
- Peptide for treating cancer7 Mar 2023US 11,597,757 B2Saint Leo University
- Cyclic peptide for treating cancer16 Feb 2021US 10,919,940 B2Saint Leo University
- Targeted augmentation of nuclear gene output30 Jun 2020US 10,696,969 B2Cold Spring Harbor Laboratory
- Targeted augmentation of nuclear gene output22 May 2018US 9,976,143 B2Cold Spring Harbor Laboratory
- Targeted augmentation of nuclear gene output28 Aug 2025US 2025/0270563 A1Cold Spring Harbor Laboratory
- Cyclic peptide for treating cancer10 Jun 2021US 2021/0171578 A1Saint Leo University
- Targeted augmentation of nuclear gene output15 Apr 2021US 2021/0108208 A1Cold Spring Harbor Laboratory
- Peptide for treating cancer1 Apr 2021US 2021/0095005 A1Saint Leo University
- Cyclic peptide for treating cancer28 Nov 2019US 2019/0359654 A1Saint Leo University
Most cited
By later US patents
- Immobilization of biologically active molecules by changing the Oxidation state of a chelated transition metal ion42US 5,439,829 AEli Lilly and Company · 1995
- Broad-spectrum tumor suppressor genes, gene products and methods for tumor suppressor gene therapy39US 5,496,731 A1996
- Genetic mechanisms of tumor suppression38US 5,532,220 AThe Regents of the University of California · 1996
- Compositions and methods for the treatment of cancer using recombinant viral vector delivery systems36US 5,789,244 ACanji, Inc. · 1998
- Targeted augmentation of nuclear gene output25US 9,976,143 B2Cold Spring Harbor Laboratory · 2018